AMT
Investors Home

Amsterdam Molecular Therapeutics (Euronext: AMT) is a leading gene therapy company, with a unique platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform.More » More »
Recent News
DateTitle
08/13/08Amsterdam Molecular Therapeutics Reports Half Year Results 2008
08/05/08AMT to Release Half Year 2008 Results on August 13, 2008
07/17/08AMT Appoints Director Global Marketing and Sales
07/15/08AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
More »
Upcoming Events
There are currently no events scheduled.
More »		 
Latest Results
Condensed Interim Financial Report June 30, 2008
Half Year 2008 Results Conference Call
Featured Report
Download Documentation Condensed Interim Financial Report June 30, 2008